Predicting mAb Pharmacokinetics in Humans with a Minimal PBPK Model

Iain Gardner

Monoclonal antibodies (mAbs) and their derivatives are a rapidly growing segment of the pharmaceutical industry’s pipeline. In fact, more than 40 mAbs and derivatives have been approved for a variety of therapeutic applications; around 500 mAbs and derivatives are currently in different stages of development. Monoclonal antibodies have pharmacokinetic (PK) properties that are quite distinct from that […]

Read More
Topics: PBPK Modeling & Simulation
Learn More
LinkedIn